Scientists Develop Experimental Universal Vaccine for Respiratory Threats

Researchers from five prominent U.S. universities, led by a team at Stanford University, have made significant progress toward creating a universal vaccine that could protect against a wide array of respiratory threats, including SARS-CoV-2, other coronaviruses, bacterial infections, and common allergens. This experimental vaccine, detailed in a study published in the journal *Science*, utilizes a novel approach that could transform vaccination practices.

Scientists develop ‘universal’ vaccine that could guard against multiple threats

The experimental vaccine, named GLA-3M-052-LS+OVA, operates differently from traditional vaccines. Instead of introducing a piece of a pathogen to train the immune system, it mimics the signals exchanged by immune cells during an infection. This method stimulates both the innate and adaptive immune responses, creating a robust and long-lasting defense. In tests conducted on mice, three doses of the vaccine provided protection for at least three months against SARS-CoV-2 and other respiratory viruses, as well as bacterial pathogens like *Staphylococcus aureus* and *Acinetobacter baumannii*. Unvaccinated mice exhibited severe illness and high mortality rates, while vaccinated mice showed only mild symptoms and effectively cleared the virus from their lungs.

Scientists develop ‘universal’ vaccine that could guard against multiple threatsUsNews and World Report

If successful in human trials, this universal vaccine could potentially replace multiple seasonal shots, offering a single solution for various respiratory illnesses, including influenza, respiratory syncytial virus (RSV), and bacterial pneumonia. Researchers anticipate that a nasal spray formulation could be available within five to seven years, providing a convenient and effective means of vaccination.

UsNews and World Report

Bali Pulendran, a professor of microbiology and immunology at Stanford, emphasized the transformative potential of this vaccine, stating, "Imagine getting a nasal spray in the fall months that protects you from all respiratory viruses." He noted that the vaccine's ability to prepare the lung immune system for rapid response is a significant advancement in immunology.

UsNews and World Report

While the findings are promising, experts caution that the results are currently limited to animal studies. The transition from animal models to human trials poses significant challenges, and there is no guarantee that the vaccine will yield similar results in humans. Critics highlight the need for rigorous testing to ensure safety and efficacy before any widespread application.

UsNews and World Report

The next steps involve initiating Phase I clinical trials to assess the safety of the vaccine in humans. Should these trials prove successful, larger studies will follow to further evaluate its effectiveness and potential for widespread use.

Scientists develop ‘universal’ vaccine that could guard against multiple threats

• "What we have is a universal vaccine against diverse respiratory threats." — Bali Pulendran, Professor, Stanford University

UsNews and World Report

• "The lung immune system is so ready and so alert that it can launch the typical adaptive responses in as little as three days." — Bali Pulendran, Professor, Stanford University

UsNews and World Report

This innovative approach to vaccination represents a significant leap forward in the quest for comprehensive protection against respiratory diseases, with the potential to reshape public health responses to future pandemics.

UsNews and World Report